BioCryst Pharmaceuticals BCRX Pre-Tax Income (Foreign)
Pre-Tax Income (Foreign) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's pre-tax income (foreign).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's pre-tax income (foreign)?
- BioCryst Pharmaceuticals (BCRX) reported pre-tax income (foreign) of $23.69M in Q4 2025.
- How has BioCryst Pharmaceuticals's pre-tax income (foreign) changed year-over-year?
- BioCryst Pharmaceuticals's pre-tax income (foreign) increased by 487.7% year-over-year, from -$6.11M to $23.69M.
- What is the long-term trend for BioCryst Pharmaceuticals's pre-tax income (foreign)?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's pre-tax income (foreign) has grown at a 43.8% compound annual growth rate (CAGR), from -$22.18M to $94.75M.
- What does pre-tax income (foreign) mean?
- Pre-tax income or loss generated from international business operations, excluding discontinued operations and tax provisions. This metric highlights the profitability and market success of the company's global footprint. It allows investors to assess the performance of foreign subsidiaries and the impact of international market conditions on overall earnings.